Figure 5. Analyses based on estimated credit assignment (CA) parameters from computational modelling (for model comparisons, based on the current and the Moran et al., 2019) data, see Appendix 1—figure 7 and Appendix 1—figure 8; for parameter recoverability, see Appendix 1—figure 9.

(A) Model-free and model-based credit assignment parameters (MFCA; MBCA) did not differ significantly for placebo (P) and levodopa (D) conditions. (B) MFCA parameters based on the informative destination for the ghost-nominated (GN) and the ghost-rejected (GR) destinations as a function of drug condition. (C) Same as B but for the non-informative destination. (D) The extent to which MFCA prefers the ghost-nominated over the ghost-rejected vehicle for each destination and drug condition. We name this preferential MFCA (PMFCA). Error bars correspond to SEM reflecting variability between participants.